EHMT2 Inhibitor Design via Local Quality and Parameter Changes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for EHMT-mediated disorders, such as sickle cell anemia and cancers, lack effective inhibitors to target the histone methyltransferase activity of EHMT1 and EHMT2, which are overexpressed in these conditions, leading to uncontrolled gene expression and proliferation.
Innovation Solution
Development of specific compounds, represented by Formulae (Va) to (Vf), which act as selective inhibitors of EHMT2, inhibiting histone methyltransferase activity with IC50 values of 1 µM or less, thereby reducing the methylation of histone lysines and modulating gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If EHMT2 inhibitors are developed to treat EHMT-mediated disorders, then the effectiveness of treatment is improved, but the specificity and potency requirements create development complexity
Solution Approach 1:
The patent applies parameter changes by systematically varying chemical parameters (substituents R1-R6, ring structures, molecular weight, logP values) to optimize EHMT2 inhibitor compounds. This involves adjusting physical-chemical properties and biological activity parameters to achieve the desired IC50 values and selectivity ratio while maintaining drug-like properties.
Solution Approach 2:
The patent applies local quality by introducing specific substituent groups at different positions (R1-R6) on the core molecular structure to enhance EHMT2 binding affinity and selectivity. Each substituent is carefully chosen to interact with specific amino acid residues in the EHMT2 active site, thereby improving treatment effectiveness through localized molecular modifications.
2Manufacturing precision
If selective EHMT2 inhibitors are designed with high potency (IC50 ≤ 1 µM), then the inhibition effectiveness is improved, but the structural complexity of compounds increases
Solution Approach 1:
The patent optimizes compound structures by adjusting parameters such as molecular weight (150-500 Da), logP (2-6), and the number of hydrogen bond donors/acceptors to achieve high EHMT2 inhibition potency while maintaining reasonable structural complexity and drug-like properties.
Solution Approach 2:
The patent employs a core molecular structure that is copied and modified with various substituent patterns to generate multiple analogs with different potencies and selectivities, allowing systematic optimization without completely redesigning the molecular framework each time.
3Measurement precision
If compounds are optimized for EHMT2 selectivity over kinases, then the specificity is improved, but the screening and validation process becomes more complex
Solution Approach 1:
The patent optimizes selectivity parameters by adjusting compound properties to achieve specific binding characteristics that differentiate EHMT2 from kinases, using parameters such as selectivity ratio (EHMT2 IC50/kinase IC50) and binding affinity constants to guide compound design and selection.
Data Source
AI summary
The present disclosure relates to substituted fused bi- or tri- heterocyclic compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering a substituted fused bi- or tri- heterocyclic compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.